VAERS Explorer
Back to explore

Report #2896079

Received May 11, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
0.3 yrs
State
OR
Recovered
Unknown
Vaccinated
Apr 24, 2026
Onset
Apr 24, 2026
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
DTAPIPVHIBDTAP + IPV + HIB (PENTACEL)SANOFI PASTEURUNKUK379AAIM / LL

Symptoms (2)

No adverse eventProduct preparation issue

Symptom narrative

pentacel was administered without the hib component with no reported adverse event; Initial information received on 24-Apr-2026 regarding an unsolicited valid non-serious case received from a health care professional (HCP). This case involves a 4-month-old male patient who was administered to Diphtheria/Tetanus/5 Hybrid Ac Pertussis/Ipv (Vero)/Hib(Prp/T) Vaccine without the hib component with no reported adverse event. The patient's past medical history, past drugs, vaccination(s), family history, concomitant medications were not provided. Concomitant medication(s) included pneumococcal vaccine conj 20v (cRM197) (Prevnar20) and rotavirus vaccine (Rotavirus vaccine). On 24-Apr-2026, the patient received a 0.5 mL intramuscular dose of Diphtheria/Tetanus/5 Hybrid Ac Pertussis/Ipv (Vero)/Hib(Prp/T) Vaccine, Powder and suspension for suspension for injection (batch/lot number: UK379AA, expiration date: 31-Mar-2027) (strength: unknown) via intramuscular route in left thigh for immunization [Immunisation]. The patient experienced pentacel was administered without the hib component with no reported adverse event (Single component of a two-component product administered, onset date: 24-Apr-2026 and latency: same day). Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Medical history

Comments: NONE

Other medications

Prevnar 20; Rotavirus vaccine